HeyJaredAntoinette F. Konski
- Indexed articles, last 90 days
- 3
- Latest publication
- Aug 12, 2026
- Outlet visibility, for natlawreview.com
- Top 1M sites
- Earliest in this view
- Jul 15, 2026
Latest articles
Global AI Patent Surge: Trends, Dominance, and Strategy (opens the original)
Read excerpt
For patent attorneys, few technology areas demand closer attention right now than artificial intelligence (“GenAI”). Two reports from the World Intellectual Property Organization (“WIPO”) bracket a two-year window: the Patent Landscape Report: Generative Artificial Intelligence published in 2024 (the “2024 Report”) and the Patent Trends Update in GenAI published in 2026 (the “2026 Report”). Together, they offer a data-driven view of how AI patenting has evolved and what that evolution means for
Practical Guidance for Pharmaceutical Method-of-Use Patent Claims After Teva v. Eli Lilly and In re Xencor (opens the original)
Read excerpt
In our companion article, Pharmaceutical Method-of-Use Claims After Teva v. Eli Lilly and In re Xencor: Written Description, Enablement, and the Known-Compound Genus, we analyzed two recent Federal Circuit decisions that offer complementary guidance on a recurring question in patent law: what must a patent specification disclose to satisfy written description and enablement under 35 U.S.C. § 112 when the claimed invention is the new use of a genus of known compounds or compositions? In Teva Phar
Pharmaceutical Method-of-Use Claims After Teva v. Eli Lilly and In re Xencor: Written Description, Enablement, and the Known-Compound Genus (opens the original)
Read excerpt
Two recent Federal Circuit decisions offer complementary guidance on a recurring question in patent law: what must a patent specification disclose to satisfy written description and enablement under 35 U.S.C. § 112 when the claimed invention is the new use of a genus of known compounds or compositions? Teva Pharm. Int’l GmbH v. Eli Lilly & Co., 172 F.4th 1367 (Fed. Cir. 2026), and In re Xencor, Inc., 130 F.4th 1350 (Fed. Cir. 2025), reach different outcomes on superficially similar facts. The co
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 1M sites
For natlawreview.com, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.